Raymond James analyst Gary Nachman initiates coverage on AbbVie (NYSE:ABBV) with a Outperform rating and announces Price Target of $177.
Pfizer Says Impact Of Tornado On Site Is Expected To Affect Supply Of Medicines From Rocky Mount Facility Until At Least Mid-2024; Begun Storing Non-Production Related Materials In A New Warehouse Secured As A Temporary Replacement To Its Hirise Warehouse
The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 51 cents per share. This marks the 399(th) consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 15, 2023, to shareholders of record at the close of business on Oct. 13, 2023. Abbott has increased its dividend payout for 51 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.
Moderna Ramps Down MRNA Drug Substance Production For Its Covid-19 Vaccine At Lonza; Will Ramp Down Production Of MRNA Drug Substance For Its Covid-19 Vaccine At Lonza’s Site In Visp, Switzerland, In Q3 2023
Moderna Continues To Expect 2023 Covid-19 Sales Of $6B-$8B, Dependent On U.S. Vaccination Rates. While the 2023 cost of sales remains elevated, the company is currently resizing its manufacturing footprint and supply base to accelerate gross margin expansion towards its longer-term target of 75-80%.
HSBC analyst Morten Herholdt initiates coverage on Zoetis (NYSE:ZTS) with a Buy rating and announces Price Target of $230.
Stifel analyst Jonathan Block reiterates Zoetis (NYSE:ZTS) with a Buy and maintains $205 price target.
AbbVie Announced Topline Results From Phase 3 SEQUENCE Trial Of Skyrizi (Risankizumab) Versus Stelara (Ustekinumab); The Study Met Its Primary Endpoint In Patients With Moderately To Severely Active Crohn’s Disease Who Have Failed One Or More Anti-TNFs.
Truist Securities analyst Robyn Karnauskas reiterates Gilead Sciences (NASDAQ:GILD) with a Buy and maintains $91 price target.
B of A Securities analyst Geoff Meacham upgrades Gilead Sciences (NASDAQ:GILD) from Neutral to Buy and raises the price target from $88 to $95.